INBRAIN’s €14.3 Million Financing Round

EY Abogados advised the investors on the transaction.

INBRAIN Neuroelectronics closed a €14.35 million Series A, one of the biggest rounds in the Spanish MedTech industry, co-led by Asabys Partners and Alta Life Sciences, joined by CDTI Innvierte (entity dependent of the Spanish Ministry of Science and Innovation) and two international investors, Vsquared Ventures, deep tech-focused early-stage VC based in Munich and TruVenturo GmbH, one of Germany’s most successful tech and life science company builders. The financing round also counts with the follow-on investment from ICF Venture Tech II, investment fund from the Institut Català de Finances.

This investment will allow the company to bring the technology for the first time to humans and to consolidate the safety of graphene as the potential new standard of care in neurotechnologies.

INBRAIN is a spin-off from the Graphene Flagship, one of the largest European research initiatives, and its partners the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA), in Spain. Established in 2019, INBRAIN uses technology developed by Graphene Flagship partners ICN2, ICREA and the University of Manchester to develop smart devices for patients with neuronal disorders, like Parkinson’s or epilepsy.

EY Abogados advised the investors on the financing round with partners Simeón Garcia-Nieto (Picture) and Jose Carnerero, together with senior lawyer Marta Berna.

Involved fees earner: Marta Berná – EY (Ernst & Young); José Carnerero Álvaro – EY (Ernst & Young); Simeón García-Nieto – EY (Ernst & Young);

Law Firms: EY (Ernst & Young);

Clients: Alta Life Sciences; Asabys Partners; ICF Venture Tech II; TruVenturo; Vsquared Ventures ;

Author: Federica Tiefenthaler